Annual Report 2008 - IVA
Annual Report 2008 - IVA
Annual Report 2008 - IVA
You also want an ePaper? Increase the reach of your titles
YUMPU automatically turns print PDFs into web optimized ePapers that Google loves.
<strong>IVA</strong> South<br />
ivA south is a central node for the activities in southern sweden.<br />
in <strong>2008</strong> issues addressed by ivA south included innovation and<br />
the innovative climate, nanotechnology and human capital’s effects<br />
on a company’s brand equity. energy and materials technology<br />
were the focus of ivA west on a visit to the new öresundsverket<br />
power plant and the höganäs AB metal powders company.<br />
Is short-sightedness threatening the<br />
future of the Swedish manufacturing<br />
industry?<br />
globalisation,<br />
fund capital and<br />
internationalisation<br />
of ownership of<br />
swedish industry<br />
have fundamentally<br />
raised expectations<br />
of company boards<br />
and management.<br />
The risk of shortsightedness<br />
has increased. sustainable profitability<br />
requires constant renewal, but the question<br />
is if companies today can really make the<br />
long-term investments in radical innovations<br />
that will form the basis for the next generation<br />
of the swedish processing and manufacturing<br />
industry. have we got the right information,<br />
methods and tools to determine if we are<br />
investing enough in business renewal, or are<br />
there some unpleasant surprises in store?<br />
These questions were the topic of lively discussion<br />
when ivA’s chairman hans dalborg,<br />
mats qviberg of hq and others debated the<br />
issues at a meeting at ivA on 8 october.<br />
Venture capital and entrepreneurship<br />
in biotechnology<br />
Biotech companies<br />
need more than a<br />
promising idea to<br />
gain momentum<br />
to develop into<br />
listed companies;<br />
they also need<br />
long-term support<br />
from financial backers.<br />
development<br />
times are long and not all ideas become<br />
profitable products. it takes time to plough<br />
through the rules and regulations that often<br />
exist in biotech contexts. when the results<br />
are in, it is important to decide how to use<br />
them. license the technology or develop it<br />
yourself? generate revenues from your own<br />
production or through royalties from other<br />
companies?<br />
At a meeting held by division x: Biotechnology,<br />
on 16 september various examples<br />
were presented of how biotech companies<br />
can be developed and what sort of support<br />
they need from backers.<br />
33<br />
<strong>IVA</strong> West<br />
ivA west is the node for the activities in western sweden. nanotechnology,<br />
energy technology, design and innovation have all been<br />
on the agenda there; for example, when ivA west focused on<br />
electrical energy from the perspective of sweden and western<br />
sweden. infrastructure issues were also explored as they relate to<br />
western sweden.<br />
Common diseases give Sweden<br />
a unique opportunity to become a<br />
leading research nation<br />
Potential for preventive<br />
measures<br />
for both physiological<br />
and psychiatric<br />
diseases may<br />
increase drastically<br />
thanks to the<br />
lifegene project<br />
at karolinska<br />
institute. As this<br />
project combines national registration data<br />
with numerous clinical studies and research<br />
projects, scientists are hoping to be able to<br />
document how genetics and the environment<br />
impact the development of our most<br />
common diseases. The project, which aims<br />
to determine the causes of common diseases<br />
such as cancer and psychiatric illness,<br />
was presented at a meeting held by division<br />
vii: Basic and interdisciplinary engineering<br />
sciences, on 10 november.